Arbutus Biopharma Corp (ABUS) Akciju cena un jaunumi

SākumlapaABUS • NASDAQ

Arbutus Biopharma Corp

4,26 $

16. marts, 08:20:34 GMT-4 · USD · NASDAQ · Atruna

AkcijaVērtspapīrs tiek tirgots šeit: ASVGalvenā biroja atrašanās vieta: ASV

Slēgšanas kurss

4,26 $

Gada diapazons

2,71 $ - 5,10 $

Tirgus kapitalizāc.

819,30 milj. USD

Vid. apjoms

2,67 milj.

P/E koeficients

Ienākumi no dividendēm

Galvenā birža

NASDAQ

Tirgus ziņas

Stock Titan

pirms 45 minūtēm

Drone cyber firm Mobilicom to detail 2025 results Mar. 23

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Industrials lead S&P 500 earnings beat on defense, AI demand

Solana Price Prediction Faces $91 Resistance After NYSE Owner Invests in OKX at $25B, but Pepeto Builds What No Other Presale Even Attempts

富途牛牛

pirms 1 stundas

Dow Jones Top Energy Headlines at 7 AM ET: Supply Shortage Will Need to Persist to Support Current Oil Price Level

.DJI

0,00%

Par

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

Ģenerāldirektors

William H. Collier

Dibināšanas datums

2007

Galvenais birojs

Warminster Township, Pensilvānija
Amerikas Savienotās Valstis

Tīmekļa vietne

arbutusbio.com

Darbinieki